GlassScriptPhysician profile
John F Bangston
NPI 1457361800
$10,442.07
in general payments reported to CMS, 2019-2025
31 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,745 · 2020: $1,818 · 2021: $1,725 · 2022: $1,015 · 2023: $940 · 2024: $1,546 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,635.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,062.04 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $845.08 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $839.07 | 2019-2022 | |
| Amgen INC. | $716.36 | 2019-2024 | Otezla, Repatha |
| Gilead Sciences, INC. | $674.15 | 2019-2023 | Veklury |
| Bayer Healthcare Pharmaceuticals INC. | $559.17 | 2023-2025 | |
| Abbvie INC. | $440.34 | 2021-2023 | Vraylar |
| Novo Nordisk INC | $424.00 | 2019-2025 | |
| Esperion Therapeutics, INC. | $360.73 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $229.65 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $220.83 | 2019-2021 | |
| Inspire Medical Systems, INC. | $219.61 | 2024 | Inspire |
| Allergan, INC. | $157.39 | 2020 | |
| Bard Peripheral Vascular, INC. | $122.51 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $121.67 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $118.48 | 2022-2023 | Shingrix |
| Teva Pharmaceuticals USA, INC. | $113.57 | 2019 | |
| Tms Neurohealth Centers INC. | $106.65 | 2025 | Tms Neurohealth Centers INC. |
| Teleflex LLC | $84.28 | 2025 | Barrigel |
| Eisai INC. | $80.97 | 2020-2021 | |
| Zoll Respicardia, INC. | $59.43 | 2024 | Remede System |
| Amarin Pharma, INC. | $58.38 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $34.80 | 2019 | |
| Medtronic, INC. | $31.80 | 2023 | Intellis Adaptivestim |
| Arbor Pharmaceuticals, INC. | $29.02 | 2019-2020 | |
| Aytu Biopharma, INC. | $23.15 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.66 | 2022 | |
| Pfizer INC. | $19.28 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.17 | 2020 | |
| Althera Pharmaceuticals LLC | $16.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bangston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.